Regulatory approval

Published by the Health Service Executive. Withdrawn

The Republic of Ireland's Health Service Executive (HSE) has approved fulvestrant for reimbursement as a treatment option for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-estrogen therapy in patients who are postmenopausal women.

This is written in the approval document as:

Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-oestrogen therapy.

Reimbursement

N/A

Citation

Fulvestrant Therapy, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6816/361_Fulvestrant_Therapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2016-11-11	Health Service Executive	Indication approved for reimbursement.